Palbociclib

SKU: P0590

Category: API's & Intermediates

Synonyms: 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one , PD 0332991 , PD-332991 , PD991 , PF 00080665; 571190-30-2
CAS-Number: C₂₄H₂₉N₇O₂
Molecular Formula: 447.53
Molecular Weight

Product Data
Handling
Safety Information
Details

Specifications

Purity: ≥98% (HPLC)
Identity: 1H-NMR
Appearance: Light-yellow or off-yellow powder, beige

Properties

Solvents: DMSO (2 mg/ml)

Short Term Storage: RT
Use / Stability: Stable for at least 2 years after receipt when stored at RT.
Handling Advice: Protect from light and moisture.
Long Term Storage: RT
Shipping: AMBIENT

Transportation: Not dangerous goods

Description: Palbociclib is a potent and selective inhibitor of CDK4 (IC50=11nM) and CDK6 (IC50=16nM). Displays selectivity for Cdk4/6 over a panel of 36 additional protein kinases. It exhibits selective antiproliferation activity against Rb-positive human breast/colon/lung/leukemia cancer cultures and displays in vivo efficacy against various advanced stage human tumor xenografts in mice. It inhibits phosphorylation of Rb protein and cell cycle progression through G1 in primary 5T33MM cells and sensitized these cells to killing by a proteasome inhibitor (bortezomib) in mouse models. Induces autophagy and senescence in AGS gastric cancer cells. It is a clinically useful breast cancer agent. In addition cell cycle inhibitors have been shown to boost tumor immunogenicity.
InChi: InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
References: (1) D.W. Fry, et al., Mol. Cancer Ther. 3, 1427 (2004) , (2) E. Menu, et al., Cancer Res. 68, 5519 (2008) , (3) R.L. Sutherland & E.A. Musgrove, Breast Cancer Res. 11, 112 (2009) , (4) R.S. Finn, et al., Breast Cancer Res. 11, R77 (2009) , (5) A. Rocca, et al., Expert Opin. Pharmacother. 15, 407 (2014) (Review) , (6) J.D. Altenburg & S.S. Farag, Expert Opin. Investig. Drugs 24, 261 (2015) (Review) , (7) A.S. Clark, et al., JAMA Oncol. 2, 253 (2016) (Review) , (8) C.A. Valenzuela, et al., Exp. Cell Res. 360, 390 (2017) , (9) S. Goel, et al., Nature 548, 471 (2017) , (10) M. Schmidt & M. Sebastian, Recent Results Cancer Res. 211, 153 (2018) (Review) , (11) M. Poratti & G. Marzaro, Eur. J. Med. Chem. 172, 143 (2019) (Review)
InChi Key: AHJRHEGDXFFMBM-UHFFFAOYSA-N
Smiles: O=C1C(C(C)=O)=C(C)C(C=NC(NC2=CC=C(N3CCNCC3)C=N2)=N4)=C4N1C5CCCC5

Palbociclib is a potent and selective inhibitor of CDK4 (IC50=11nM) and CDK6 (IC50=16nM). Displays selectivity for Cdk4/6 over a panel of 36 additional protein kinases. It exhibits selective antiproliferation activity against Rb-positive human breast/colon/lung/leukemia cancer cultures and displays in vivo efficacy against various advanced stage human tumor xenografts in mice. It inhibits phosphorylation of Rb protein and cell cycle progression through G1 in primary 5T33MM cells and sensitized these cells to killing by a proteasome inhibitor (bortezomib) in mouse models. Induces autophagy and senescence in AGS gastric cancer cells. It is a clinically useful breast cancer agent. In addition cell cycle inhibitors have been shown to boost tumor immunogenicity.

Artikelnummer: P0590 Kategorie: API's & Intermediates

Zusätzliche Information

Zusätzliche Information

Synonyms	6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one, PD 0332991, PD-332991, PD991, PF 00080665
Purity	≥98% (HPLC)
Appearance	Light-yellow or off-yellow powder, beige
CAS-Number	571190-30-2
Molecular Formula	C24H29N7O2
Molecular Weight	447.53
Identity	1H-NMR
Solvents	DMSO (2 mg/ml)
Smiles	O=C1C(C(C)=O)=C(C)C(C=NC(NC2=CC=C(N3CCNCC3)C=N2)=N4)=C4N1C5CCCC5
InChi Key	AHJRHEGDXFFMBM-UHFFFAOYSA-N
Shipping	AMBIENT
Short Term Storage	RT
Long Term Storage	RT
Handling Advice	Protect from light and moisture.
Use / Stability	Stable for at least 2 years after receipt when stored at RT.
Transportation	Not dangerous goods
References	(1) D.W. Fry, et al., Mol. Cancer Ther. 3, 1427 (2004), (2) E. Menu, et al., Cancer Res. 68, 5519 (2008), (3) R.L. Sutherland & E.A. Musgrove, Breast Cancer Res. 11, 112 (2009), (4) R.S. Finn, et al., Breast Cancer Res. 11, R77 (2009), (5) A. Rocca, et al., Expert Opin. Pharmacother. 15, 407 (2014) (Review), (6) J.D. Altenburg & S.S. Farag, Expert Opin. Investig. Drugs 24, 261 (2015) (Review), (7) A.S. Clark, et al., JAMA Oncol. 2, 253 (2016) (Review), (8) C.A. Valenzuela, et al., Exp. Cell Res. 360, 390 (2017), (9) S. Goel, et al., Nature 548, 471 (2017), (10) M. Schmidt & M. Sebastian, Recent Results Cancer Res. 211, 153 (2018) (Review), (11) M. Poratti & G. Marzaro, Eur. J. Med. Chem. 172, 143 (2019) (Review)
InChi	InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
Quantity	5 mg, 25 mg, Bulk